Now in its second edition, this comprehensive handbook provides a state-of-the-art overview of recent advances in drug and non-drug therapies for obesity and diabetes. It also addresses major comorbidities, covering topics such as, cardiovascular diseases, renal and neuropsychiatric disorders, appetite control and micro RNAs. Special attention is also devoted to pediatric care, including the latest recommendations for therapy and prevention. Obesity and type 2 diabetes are among the top global health-care budget concerns worldwide and impact professional practice at all levels: in hospitals, clinics and physicians' offices alike. They prominently feature in headlines, and virtually no family, community or country is exempt from their protean, deleterious consequences. Furthermore, given the multiple intersections in their pathways, they often go hand in hand. The good news is that scientific advances in all fields, including genomics, metabolomics, lipidomics and microbiomics, are increasing our understanding of these two disease areas. At the same time, artificial intelligence, machine learning, mobile health and advanced implantable and external devices are rendering prevention and management more available, safe and cost-effective. In addition, bariatric and metabolic surgery has evolved from a niche specialty to an officially endorsed option for several modalities of obesity and diabetes. This book presents the latest lifestyle, pharmacological, surgical and non-surgical treatment options, including endoscopic intervention and cell therapy. Objectively reviewing natural and artificial sweeteners and critically examining issues such as public health initiatives, government mandated taxes for unhealthy foods and environmental planning, no stone is left unturned in gathering the latest practical information. As such, the book will appeal to seasoned specialists, as well as students and healthcare professionals in training.

Obesity and diabetes develop as a complex result of genetic, metabolic and environmental factors and are characterized by increased lipogenesis and lipid accumulation in many tissues. Stearoyl-CoA desaturase (SCD) genes are a critical regulator of lipogenesis and catalyzes the synthesis of monounsaturated fatty acids (MUFA), mainly oleoyl- (18:1n9) and palmitoleoyl-CoA (16:1n7). These MUFAs are the major fatty acid substrates for the synthesis of triglycerides, cholesterol esters, wax esters and membrane phospholipids. There are 4 SCD isoforms (SCD1-4) in mice and two (hSCD1 and hSCD5) expressed in humans. At first glance, stearoyl-CoA desaturase enzyme would be considered a housekeeping enzyme because it synthesizes oleate a well-known fatty acid that is abundant in many dietary sources. However numerous studies have shown that SCD is a very highly regulated enzyme that features in so many physiological processes ranging from fat differentiation, carbohydrate and fat metabolism, inflammation and cancer. The editor's studies using stearoyl-CoA desaturase knockout (SCD1-/-) mice and studies of other investigators using pharmacological approaches to reduce SCD1 expression in mouse tissues have all established that the expression of SCD1 gene isoform represents a key step in partitioning of lipids between storage and oxidation. High SCD expression favors fat storage leading to obesity while reduced SCD expression favors fat burning and leanness. Although these studies clearly illustrated that SCD1 expression is involved in the development of obesity and insulin resistance, questions remain in the elucidation of the mechanisms involved and role of SCD1. This book includes chapters by leading researchers on SCD Genes in the brain, heart, muscle, liver metabolism, Colitis, and more.

Hormonal influences, both natural and iatrogenic, are implicated in the most frequent health issues of women. Endometrial cancer is now the most common gynecologic cancer in the United States and the industrialized world. This cancer is strongly related to hormonal and metabolic factors. In addition, breast cancer treated with hormone therapy (Tamoxifen) may, in some cases, be associated with uterine pathology. Hormone therapy is used to improve the physiological effects and counteract abnormal and deleterious effects of "natural" hormonal activity. Millions of women receive hormone therapy at some point of their life: using oral contraceptives, reproductive technology, treatment for post-menopausal symptoms, among other uses. This book addresses a range of women's health issues, from fertility to neoplasms, and their relationship with natural and iatrogenic hormonal effects. Chapters include clinical and pathological descriptions, theoretical and practical medical issues, and original studies and cases. Controversial issues in certain hormone therapies are presented with updated concepts based on clinical studies and novel statistical methods. The book will be useful for specialized and general physicians, oncologists, endocrinologists, researchers, medical students, and others in the field of women's health.

This book illustrates the importance and significance of oxidative stress in the pathophysiology of various human diseases. The book initially introduces the phenomenon of oxidative stress, basic chemical characteristics of the species involved and summarizes the cellular oxidant and anti-oxidant system and the cellular effects and metabolism of the oxidative stress. In addition, it reviews the current understanding of the potential impact of oxidative stress on telomere shortening, aging, and age-related diseases. It also examines the role of oxidative stress in chronic diseases, including cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders. Further, the book presents novel technologies for the detection of oxidative stress biomarkers using nanostructure biosensors, as well as in vitro and in vivo models to monitor oxidative stress. Lastly, the book addresses the drug delivery carriers that can help in combating oxidative stress.

Diabetes can limit blood supply to the feet resulting in loss of feeling, which means foot injuries do not heal well and may go unnoticed. People with diabetes are 15 times more likely to have a limb amputated due to gangrene. Diabetic foot is an often overlooked complication in general diabetes care. This book is a practical guide to the management of diabetes-related complications of the foot. Beginning with an overview of diabetic foot care, anatomy and biomechanics of the foot, and peripheral neuropathy, the following sections cover a variety of diabetes-related disorders. Each condition is explained in detail covering its pathophysiology, investigations, diagnosis and treatment, including surgery and rehabilitation where appropriate. The final section discusses recent advances and future techniques and technologies in the management of diabetic foot. The text is further enhanced by algorithms and diagrams to assist understanding of potential treatment strategies.

The world is faced with an epidemic of metabolic diseases such as obesity and type 2 diabetes. This is due to changes in dietary habits and the decrease in physical activity. Exercise is usually part of the prescription, the first line of defense, to prevent or treat metabolic disorders. However, we are still learning how and why exercise provides metabolic benefits in human health. This open access volume focuses on the cellular and molecular pathways that link exercise, muscle biology, hormones and metabolism. This will include novel "myokines" that might act as new therapeutic agents in the future.

This book provides a pioneering approach to modeling the human diabetic patient using a software agent. It is based on two MASc (Master of Applied Science) theses: one looking at the evolution of the patient agent in time, and another looking the interaction of the patient agent with the healthcare system. It shows that the software agent evolves in a manner analogous to the human patient and exhibits typical attributes of the illness such as reacting to food consumption, medications, and activity. This agent model can be used in a number of different ways, including as a prototype for a specific human patient with the purpose of helping to identify when that patient's condition deviates from normal variations. The software agent can also be used to study the interaction between the human patient and the health care system. This book is of interest to anyone involved in the management of diabetic patients or in societal research into the management of diabetes. The diabetic patient agent was developed using the Ackerman model for diabetes, but this model can be easily adapted for any other model subject with the necessary physiological data to support that model.